Interferon Responsiveness in Patients Infected with Hepatitis C Virus 1b Differs Depending on Viral Subtype

Overview

Journal Gut

Specialty Gastroenterology

Date 2001 Jul 17

PMID 11454804

Authors

I Nakano

Y Fukuda

Y Katano

H Toyoda

K Hayashi

T Hayakawa

T Kumada

S Nakano

Affiliations

Soon will be listed here.

Abstract

Background: Genotype 1b of hepatitis C virus (HCV) comprises mainly three subtypes, each named for its geographic prevalence (worldwide, W; Japan, J; and not in Japan, NJ).

Aim: To characterise the newly identified subtypes of genotype 1b and to review factors associated with response to interferon (IFN) for each subtype.

Patients: Chronic hepatitis patients (80 men and 41 women; mean age 48.5 years, range 20.7--69.3) with HCV genotype 1b (W type, n=41; J type, n=38) or genotype 2a (n=42) were treated according to the same IFN protocol. Forty four patients (36.4%) negative for serum HCV RNA six months after cessation of treatment were considered complete responders.

Methods: Factors associated with complete response were investigated.

Results: Genotype 2a patients had lower viral loads (odds ratio 0.11 (95% confidence intervals (CI) 0.049--0.256)) and a better IFN response (odds ratio 0.25 (95% CI 0.117--0.552)) than genotype 1b patients whereas W type and J type patients had similar viral loads and responses to IFN. IFN response in W type patients was associated with female sex (odds ratio 0.23 (95% CI 0.055--0.983)) and low viral load (odds ratio 84.00 (95% CI 14.04--502.6)) whereas response in J type patients was related to transfusion history (odds ratio 7.20 (95% CI 1.443--35.91)), low viral load (odds ratio 117.0 (95% CI 17.82--768.3)), and genetic mutation in the interferon sensitivity determining region of the virus (odds ratio 0.08 (95% CI 0.013--0.553)). Multivariate analysis found low viral load (odds ratio 64.19 (95% CI 14.66--281.06)) to be the only significant independent factor associated with IFN response.

Conclusions: Factors associated with IFN responsiveness in HCV infection differ with viral subtype.

References

Watson J, Brind A, Chapman C, Bates C, Gould F, Johnson S . Hepatitis C virus: epidemiology and genotypes in the north east of England. Gut. 1996; 38(2):269-76. PMC: 1383036. DOI: 10.1136/gut.38.2.269. View

Kobayashi M, Tanaka E, Sodeyama T, Urushihara A, Matsumoto A, Kiyosawa K . The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses. Hepatology. 1996; 23(4):695-9. DOI: 10.1053/jhep.1996.v23.pm0008666319. View

Zein N, Rakela J, Krawitt E, Reddy K, Tominaga T, Persing D . Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med. 1996; 125(8):634-9. DOI: 10.7326/0003-4819-125-8-199610150-00002. View

Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P . Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology. 1996; 24(4):778-89. DOI: 10.1002/hep.510240405. View

Smith D, Pathirana S, Davidson F, Lawlor E, Power J, Yap P . The origin of hepatitis C virus genotypes. J Gen Virol. 1997; 78 ( Pt 2):321-8. DOI: 10.1099/0022-1317-78-2-321. View

Zeuzem S, Lee J, Roth W . Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa. Hepatology. 1997; 25(3):740-4. DOI: 10.1002/hep.510250341. View

Poynard T, Bedossa P, Opolon P . Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997; 349(9055):825-32. DOI: 10.1016/s0140-6736(96)07642-8. View

Dubois F, Desenclos J, Mariotte N, Goudeau A . Hepatitis C in a French population-based survey, 1994: seroprevalence, frequency of viremia, genotype distribution, and risk factors. The Collaborative Study Group. Hepatology. 1997; 25(6):1490-6. DOI: 10.1002/hep.510250630. View

Shiratori Y, Kato N, Yokosuka O, Imazeki F, Hashimoto E, Hayashi N . Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology. 1997; 113(2):558-66. DOI: 10.1053/gast.1997.v113.pm9247476. View

10.

Khorsi H, Castelain S, Wyseur A, Izopet J, Canva V, Rombout A . Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients. J Hepatol. 1997; 27(1):72-7. DOI: 10.1016/s0168-8278(97)80282-6. View

11.

Manesis E, Papaioannou C, Gioustozi A, Kafiri G, Koskinas J, Hadziyannis S . Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6 or 12 months: a 4-year follow-up of 211 patients. Hepatology. 1997; 26(3):734-9. DOI: 10.1002/hep.510260327. View

12.

Akiyoshi F, Sata M, Uchimura Y, Suzuki H, Tanikawa K . Hepatic iron stainings in chronic hepatitis C patients with low HCV RNA levels: a predictive marker for IFN therapy. Am J Gastroenterol. 1997; 92(9):1463-6. View

13.

Schlaak J, Trippler M, Ernst I, Meyer zum Buschenfelde K, Gerken G . Chronic hepatitis C: the viral load per liver cell before treatment as a new marker to predict long-term response to IFN-alpha therapy. J Hepatol. 1998; 27(5):917-21. DOI: 10.1016/s0168-8278(97)80331-5. View

14.

Takagi H, Takehara K, Shimoda R, Kakizaki S, Takayama H, Abe T . Prediction of effect of interferon on chronic hepatitis C. Dig Dis Sci. 1997; 42(11):2270-6. DOI: 10.1023/a:1018866717753. View

15.

Lopez-Labrador F, Ampurdanes S, Forns X, Castells A, Saiz J, Costa J . Hepatitis C virus (HCV) genotypes in Spanish patients with HCV infection: relationship between HCV genotype 1b, cirrhosis and hepatocellular carcinoma. J Hepatol. 1998; 27(6):959-65. DOI: 10.1016/s0168-8278(97)80137-7. View

16.

Bellobuono A, Mondazzi L, Tempini S, Silini E, Ideo G . Prospective comparison of four lymphoblastoid interferon alpha schedules for chronic hepatitis C. A multivariate analysis of factors predictive of sustained response to treatment. Eur J Gastroenterol Hepatol. 1998; 9(12):1169-77. View

17.

Izopet J, Payen J, Alric L, Sandres K, Charlet J, Vinel J . Baseline level and early suppression of serum HCV RNA for predicting sustained complete response to alpha-interferon therapy. J Med Virol. 1998; 54(2):86-91. DOI: 10.1002/(sici)1096-9071(199802)54:2<86::aid-jmv3>3.0.co;2-k. View

18.

Kleter B, Brouwer J, Nevens F, van Doorn L, Elewaut A, Versieck J . Hepatitis C virus genotypes: epidemiological and clinical associations. Benelux Study Group on Treatment of Chronic Hepatitis C. Liver. 1998; 18(1):32-8. View

19.

Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S . Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology. 1998; 27(5):1394-402. DOI: 10.1002/hep.510270529. View

20.

Kaserer K, Fiedler R, Steindl P, Muller C, Wrba F, Ferenci P . Liver biopsy is a useful predictor of response to interferon therapy in chronic hepatitis C. Histopathology. 1998; 32(5):454-61. DOI: 10.1046/j.1365-2559.1998.00413.x. View